Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From William Looney
Personalized medicine is focused on meeting patients’ needs, but it also has the potential to transform the delivery and financing of health care. In Vivo probes the path toward meeting both goals in an in-depth nterview with Eleanor Perfetto, SVP for strategic initiatives at the National Health Council, the DC-based patient advocacy organization whose members include groups representing 133 million patients nationwide.
In a series of meetings and workshops over the past 18 months, the National Health Council has developed a platform that consolidates the patient community’s perspective on how to assess value in choosing among alternative therapies in biopharmaceuticals and other key health care interventions.
Opko Health has created a dedicated R&D team to explore solutions for conditions that impair patients' quality of life.
With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model.
What Phillip Frost looks for when evaluating potential strategic partners.
Entering 2017 with freshly approved Spinraza and new CEO Michel Vounatsos, Biogen still faces challenges and uncertainty. A poll of investors highlights expectations for the company.